Sales of Stelara, a drug that treats psoriasis and psoriatric arthritis, were 15 percent higher than expected. (Photo: Jojo/Wikimedia Commons)

(Bloomberg) — Johnson & Johnson increased its full-year profit and sales forecast after second-quarter profit topped analysts’ estimates, driven by growth in the pharmaceutical division, home to blockbuster products such as arthritis treatment Remicade.

Related: Arthritis: Outcomes vary in disability insurance cases

The shares rose 3.1 percent to $127 at 7:18 a.m. in New York, before the markets opened. The stock has been trading at all-time highs as J&J relies on prescription medicines like Remicade and psoriasis drug Stelara to drive sales and stem a slowdown from the medical devices division. Remicade accounted for about 20 percent of drug revenue for the New Brunswick, New Jersey-based company last quarter.

The world’s biggest maker of health care products raised its earnings forecast to $6.63 to $6.73 a share, excluding some items, from $6.53 to $6.68 previously. Analysts anticipated $6.61.

In the second quarter, earnings were $1.74 a share, excluding some items, compared with the $1.68 average of 20 predictions compiled by Bloomberg. Drug sales increased 8.9 percent during the period, helping offset a decline in consumer products, while revenue from medical devices were little changed.

Here are the highlights for the second-quarter:

Sales were up 3.9 percent to $18.5 billion. Analysts anticipated $18 billion. Net income declined 11 percent to $4 billion, or $1.43 a share, from $4.52 billion, or $1.61 a share

Drug sales:

  • Remicade (arthritis, psoriasis and Crohn’s disease): $1.78 billion, vs. an estimate of $1.71 billion. (4.1 percent better than expected.)

  • Stelara (psoriasis and psoriatic arthritis): $804 million, vs. an estimate of $699 million. (15 percent better than expected.)

  • Zytiga (prostate cancer): $601 million, vs. an estimate of $551.3 million. (9.1 percent better than expected.)

  • Xarelto (blood thinner): $594, vs an estimate of $563.5 million. (%.4 percent better than expected.)

Sales at the consumer business — which includes Johnson’s baby-care products, Neutrogena and Listerine — fell 1.8 percent from the previous year. The company’s medical device sales increased by 0.8 percent versus the previous year

J&J’s shares have almost doubled since the start of 2010 as its drug division sales grew 9 points to 45 percent of revenue. The company has topped earnings estimates every period since the 2010 fourth quarter.

Related:

The 10 costliest drugs covered by Medicare Part D

9 conditions to watch for before submitting your app

Have you followed us on Facebook?

Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.